Literature DB >> 15163433

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

Yeo Hyeon Hwang1, Jong Young Choi, Soyoun Kim, Eun Sun Chung, Taeuk Kim, Sang Seok Koh, Bogman Lee, Si Hyun Bae, Jin Kim, Young Min Park.   

Abstract

Liver cirrhosis accompanies at least 70% of hepatocellular carcinomas world-wide. To evaluate the dysregulation of apoptosis and the MAPK pathway in hepatocarcinogenesis, we investigated the expression profiles of the genes involved in apoptosis and MAPK pathway in cirrhosis and hepatocellular carcinoma. A total of 94 tissue specimens (61 cirrhosis and 33 hepatocellular carcinoma) obtained from 67 patients were analyzed by microarray, quantitative PCR and Western blot experiments. Of 71 apoptosis-associated genes, c-raf-1 and S6 were up-regulated in 42.9% and 32.1% of 28 cirrhosis tissues, respectively, and both genes were well correlated in a five-cluster K-means analysis. For c-raf-1 and down stream genes in the MAPK pathway, c-raf-1, MEK, and MAPK were up-regulated in 40%, 80%, and 86.7% of 45 cirrhosis specimens, respectively, and in 50%, 63.6%, and 59.1% of 22 hepatocellular carcinoma specimens, respectively. Western blot analysis showed that activated Raf-1 was over-expressed in 91.2% (52/57) of cirrhosis and in 100% (30/30) of hepatocellular carcinoma. The expression level of Raf-1 in 14 of 26 paired samples (53.8%) was significantly higher in hepatocellular carcinoma than in cirrhosis ( [Formula: see text] -fold, [Formula: see text] ). These results suggest that the activation of Raf-1 plays an important role in the development of hepatocellular carcinoma.

Entities:  

Year:  2004        PMID: 15163433     DOI: 10.1016/j.hepres.2004.02.009

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  36 in total

Review 1.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

3.  Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.

Authors:  Jiaming Zhou; Li Chen; Yixin Zhang; Yuanyuan Wu; Guilan Wang; Song He; Zhongying Guo; Yingze Wei
Journal:  J Mol Histol       Date:  2013-10-15       Impact factor: 2.611

Review 4.  Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.

Authors:  Yasunobu Matsuda; Takafumi Ichida; Manabu Fukumoto
Journal:  Med Mol Morphol       Date:  2011-09-16       Impact factor: 2.309

5.  Saikosaponin a and saikosaponin d inhibit proliferation and migratory activity of rat HSC-T6 cells.

Authors:  Ming Feng Chen; Chao Cheng Huang; Pei Shan Liu; Chang Han Chen; Li Yen Shiu
Journal:  J Med Food       Date:  2013-09       Impact factor: 2.786

6.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

7.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.

Authors:  Zhe Zhang; Xiaoyun Zhou; Hujia Shen; Dexing Wang; Yanhong Wang
Journal:  BMC Med       Date:  2009-08-24       Impact factor: 8.775

9.  Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Authors:  Junji Furuse
Journal:  Biologics       Date:  2008-12

10.  Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

Authors:  Andrew X Zhu
Journal:  BMC Med       Date:  2009-08-24       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.